Impact of a Disease-Associated Dynactin Variant on Motile Phenomena in Lung Epithelial Cells

疾病相关的 Dynactin 变体对肺上皮细胞运动现象的影响

基本信息

  • 批准号:
    10704306
  • 负责人:
  • 金额:
    $ 36.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-22 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary The microtubule-based motor, cytoplasmic dynein-1, is best known for providing motile functions in membrane trafficking and mitosis. Complete abrogation of dynein function yields gross cellular and organismal defects that preclude detection of its contributions to other important cellular phenomena. The work described in this proposal focuses on a human dynein variant, DCTN4Y270C, that is associated with increased risk of extreme lung pathology. DCTN4Y270C (rs35772018) was first identified as a genetic modifier of cystic fibrosis but has also been associated with increased risk of lung adenocarcinoma and acute respiratory distress syndrome following sepsis. Homozygous DCTN4Y270C has no obvious impact on its own, indicating that any defects associated with DCTN4Y270C exacerbate pathology but do not cause it directly. Lung epithelial cells must be able to undergo a reversible epithelial-mesenchyme transition (EMT) to provide the ongoing wound-healing that is required for repair and maintenance of the airway. Imbalance in reversible EMT is believed to underlie the fibrosis seen in severe lung disease. Phenotypically, DCTN4Y270C expression yields reduced cell movement into experimental wounds and facilitates acquisition of epithelial polarity, both hallmarks of the mesenchyme-epithelial transition (MET). Transcriptionally, cultured bronchial epithelial cells expressing DCTN4Y270C show with hallmarks characteristic of EMT. These incongruent findings indicate that DCTN4Y270C positions cells in an aberrant, yet tolerated, state that lies between epithelia and mesenchyme, similar to the partial EMT seen in tumors. The overarching goal of the proposed work is to understand how DCTN4Y270C affects lung cell biology, specifically the cytoskeleton- dependent phenomena that underlie directed cell migration. To obtain mechanistic insight into how DCTN4Y270C alters cell function we determined the interactomes of DCTN4WT and DCTN4Y270C using BioID proximity biotinylation. This revealed a small cohort of differential interactors that others have linked to the phenomena we know to be altered in cells expressing DCTN4Y270C. The aims of this project are to establish mechanistic connections between dynein/dynactin and these novel interactors, taking advantage of DCTN4Y270C as a unique tool for modulating and perturbing cell function.
项目摘要 基于微管的马达,细胞质动力蛋白-1,最为人所知的是提供运动功能, 膜运输和有丝分裂。动力蛋白功能的完全消除产生了大量的细胞和 有机体缺陷,妨碍检测其对其他重要细胞现象的贡献。的 这项提案中描述的工作集中在人类动力蛋白变体DCTN 4 Y270 C上,该变体与以下疾病相关: 会增加肺部严重病变的风险DCTN 4 Y270 C(rs35772018)首次被鉴定为一种遗传性 但也与肺腺癌的风险增加有关, 脓毒症后急性呼吸窘迫综合征纯合子DCTN 4 Y270 C对 这表明与DCTN 4 Y270 C相关的任何缺陷都会加剧病理,但不会导致病理 直接. 肺上皮细胞必须能够经历可逆的上皮-间充质转化(EMT), 提供修复和维护气道所需的持续伤口愈合。不平衡 可逆EMT被认为是严重肺病中所见纤维化的基础。表型,DCTN 4 Y270 C 表达产生减少的细胞运动到实验伤口中,并促进上皮细胞的获得。 极性,两者都是间充质-上皮转化(MET)的标志。转录,培养 表达DCTN 4 Y270 C的支气管上皮细胞显示出EMT的特征性标志。这些 不一致的发现表明,DCTN 4 Y270 C将细胞定位在一种异常但可耐受的状态, 在上皮和间质之间,类似于在肿瘤中看到的部分EMT。的首要目标 拟议的工作是了解DCTN 4 Y270 C如何影响肺细胞生物学,特别是细胞骨架- 依赖性现象是定向细胞迁移的基础。 为了获得DCTN 4 Y270 C如何改变细胞功能的机制,我们确定了DCTN 4 Y270 C的相互作用组。 使用BioID邻近生物素化的DCTN 4 WT和DCTN 4 Y270 C。这揭示了一个小队列的差异 其他人已经将其与我们所知的细胞表达改变的现象联系起来, DCTN4Y270 C。本项目的目的是建立动力蛋白/动力蛋白之间的机制联系 这些新型的相互作用,利用DCTN 4 Y270 C作为一种独特的工具, 扰乱细胞功能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TRINA A SCHROER其他文献

TRINA A SCHROER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TRINA A SCHROER', 18)}}的其他基金

REGULATION OF CYTOPLASMIC DYNEIN BASED VESICLE TRANSPORT
基于细胞质动力蛋白的囊泡运输的调节
  • 批准号:
    8171285
  • 财政年份:
    2010
  • 资助金额:
    $ 36.69万
  • 项目类别:
REGULATION OF CYTOPLASMIC DYNEIN BASED VESICLE TRANSPORT
基于细胞质动力蛋白的囊泡运输的调节
  • 批准号:
    7957806
  • 财政年份:
    2009
  • 资助金额:
    $ 36.69万
  • 项目类别:
REGULATION OF CYTOPLASMIC DYNEIN BASED VESICLE TRANSPORT
基于细胞质动力蛋白的囊泡运输的调节
  • 批准号:
    7723664
  • 财政年份:
    2008
  • 资助金额:
    $ 36.69万
  • 项目类别:
Molecular mechanism of SIF formation by Salmonella Typhimurium
鼠伤寒沙门氏菌形成SIF的分子机制
  • 批准号:
    7197072
  • 财政年份:
    2007
  • 资助金额:
    $ 36.69万
  • 项目类别:
Molecular mechanism of SIF formation by Salmonella Typhimurium
鼠伤寒沙门氏菌形成SIF的分子机制
  • 批准号:
    7339653
  • 财政年份:
    2007
  • 资助金额:
    $ 36.69万
  • 项目类别:
MICROTUBULE BASED VESICLE TRANSPORT IN POLARIZED EPITHELIA
极化上皮中基于微管的囊泡运输
  • 批准号:
    6564275
  • 财政年份:
    2002
  • 资助金额:
    $ 36.69万
  • 项目类别:
MICROTUBULE BASED VESICLE TRANSPORT IN POLARIZED EPITHELIA
极化上皮中基于微管的囊泡运输
  • 批准号:
    6410323
  • 财政年份:
    2001
  • 资助金额:
    $ 36.69万
  • 项目类别:
MICROTUBULE BASED VESICLE TRANSPORT IN POLARIZED EPITHELIA
极化上皮中基于微管的囊泡运输
  • 批准号:
    6301128
  • 财政年份:
    2000
  • 资助金额:
    $ 36.69万
  • 项目类别:
MICROTUBULE BASED VESICLE TRANSPORT IN POLARIZED EPITHELIA
极化上皮中基于微管的囊泡运输
  • 批准号:
    6105498
  • 财政年份:
    1999
  • 资助金额:
    $ 36.69万
  • 项目类别:
MICROTUBULE BASED VESICLE TRANSPORT IN POLARIZED EPITHELIA
极化上皮中基于微管的囊泡运输
  • 批准号:
    6270727
  • 财政年份:
    1998
  • 资助金额:
    $ 36.69万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 36.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了